Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

NCT06013618 is registered in ClinicalTrials.gov with Sun Yat-Sen University Cancer Center as lead sponsor.

NCT NCT06013618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06013618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Lead sponsor
Sun Yat-Sen University Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
June 19, 2023
Completion date
December 31, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma